Cabaletta Bio Inc (OQ:CABA)

Sep 25, 2020 08:00 am ET
Cabaletta Bio to Present at Upcoming Investor Conferences in October
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D.,...
Sep 08, 2020 08:00 am ET
Cabaletta Bio to Present at Multiple Upcoming September Investor Conferences
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced its participation in fireside...
Aug 25, 2020 08:00 am ET
Cabaletta Bio Announces Publication of Comprehensive Preclinical Study Results for DSG3-CAART in Pemphigus Vulgaris
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced comprehensive preclinical...
Aug 06, 2020 07:30 am ET
Cabaletta Bio Reports Second Quarter 2020 Financial Results and Provides Business Update 
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced financial results for the...
Aug 03, 2020 08:00 am ET
Cabaletta Bio to Present at Multiple August Investor Conferences
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced its participation in fireside...
Jul 07, 2020 08:00 am ET
Cabaletta Bio and Artisan Bio Announce Gene Editing Research and Collaboration Agreement to Develop Next-Generation CAAR T Cell Therapies
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, and Artisan Bio, Inc., a precision cell...
May 28, 2020 08:00 am ET
Cabaletta Bio Announces Expansion of Sponsored Research Agreement with the University of Pennsylvania
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced the expansion of its Sponsored...
May 27, 2020 08:00 am ET
Cabaletta Bio to Present at Jefferies Virtual Healthcare Conference
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D.,...
May 18, 2020 04:30 pm ET
Cabaletta Bio Announces Presentation of Data Supporting MuSK-CAART Development for the Treatment of the MuSK form of Myasthenia Gravis at the AAN 2020 Science Highlights Virtual Platform
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that in vivo data...
May 12, 2020 07:00 am ET
Cabaletta Bio Reports First Quarter 2020 Financial Results and Provides Business Update
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced financial results for the...
May 06, 2020 08:00 am ET
Cabaletta Bio Receives FDA Fast Track Designation for DSG3-CAART for the Treatment of Mucosal Pemphigus Vulgaris
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for DSG3-CAART (Desmoglein 3 Chimeric AutoAntibody Receptor T cells), the Company’s lead product candidate for treatment of mucosal pemphigus vulgaris (mPV), for improving healing of mucosal blisters in patients with mPV.
Mar 30, 2020 07:00 am ET
Cabaletta Bio Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced financial results for the...
Feb 20, 2020 08:00 am ET
Cabaletta Bio to Present at the Cowen and Company 40th Annual Health Care Conference
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D.,...
Jan 29, 2020 08:00 am ET
FDA Grants DSG3-CAART Orphan Drug Designation for the Treatment of Pemphigus Vulgaris
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that the U.S. Food and Drug...
Nov 26, 2019 08:00 am ET
Cabaletta Bio to Present at the Evercore ISI 2nd Annual HealthCONx Conference
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D.,...
Oct 25, 2019 07:36 am ET
Cabaletta Bio Announces Pricing of Initial Public Offering
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced the pricing of its initial...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.